MedTrace Logo

A Study to Evaluate the Efficacy and Safety of AD-203

NCT04066530 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 475

Last updated 2020-12-02

No results posted yet for this study

Summary

This is a multicenter, active-controlled , randomized, double-blinded, paralleled group clinical study to evaluate the efficacy and safety of AD-203 to demonstrate the non-inferiority of AD-203 compared with Mucosta tab. in patients with acute or chronic gastritis

Conditions

  • Acute Gastritis
  • Chronic Gastritis

Interventions

DRUG

AD-203

AD-203 administered two times daily for two weeks

DRUG

Mucosta tab.

Mucosta tab. administered three times daily for two weeks

Sponsors & Collaborators

  • Addpharma Inc.

    lead INDUSTRY

Principal Investigators

  • JongJae Park, Ph.D · Korea University Guro Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-09-23
Primary Completion
2020-02-26
Completion
2020-02-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04066530 on ClinicalTrials.gov